secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rani Therapeutics Holdings, Inc. (RANI)
CIK:        0001856725
Form:       8-K
Filed at:   2024-06-24T23:59:59+00:00
Accession:  0001193125-24-166293
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rani Therapeutics and ProGen partner on GLP-1/GLP-2 dual agonist PG-102 in RaniPill HC for weight management
--------------------------------------------------------------------------------

- Parties will share development costs and operating profits/losses equally; Rani leads US, Canada, Europe, Australia development after Phase 2.
- ProGen supplies PG-102; Rani manufactures final Product (Device + compound) worldwide.
- Each party can opt-out anytime; continuing party pays low single to mid-single digit royalties on net sales post opt-out.
- Priority regulatory markets include US, EU, UK, Canada, Australia, Japan, and South Korea.
- Rani leads preclinical through Phase 1 globally; commercial rights split by assigned territories.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1856725/000119312524166293/0001193125-24-166293-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1856725/000119312524166293/d841207d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-166293

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer